This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Aydin, O. F. Articles by Gürer, Y.K. Y. Search for Related Content PubMed PubMed Citation Articles by Aydin, O. F. Articles by Gürer, Y.K. Y. Social Bookmarking                   What's this?

Combined Treatment With Subcutaneous Interferon-, Oral Isoprinosine, and Lamivudine for Subacute Sclerosing Panencephalitis

Department of Pediatric Neurology Dr. Sami Ulus Children's Hospital, Ankara, Turkey, ofaydin{at}yahoo.com.

Nesrin enbil, MD

Department of Pediatric Neurology Dr. Sami Ulus Children's Hospital, Ankara, Turkey

Necdet Kuyucu, MD

Department of Pediatrics Faculty of Medicine, University of Mersin, Mersin, Turkey

Y.K. Yavuz Gürer, MD

Department of Pediatric Neurology Dr. Sami Ulus Children's Hospital, Ankara, Turkey

We compared patients with subacute sclerosing panencephalitis who received treatment according to our protocol for at least 6 months (19 patients) with the patients who could not receive any treatment (13 patients). The treatment protocol consisted of oral isoprinosine (100 mg/kg/day), subcutaneous interferon alpha-2a (10 mU/m²/three times a week), and oral lamivudine (10 mg/kg/day). There were no statistical differences between the two groups according to Neurological Deficit Index, clinical stage, and average age on admission and also on the final evaluation after treatment. The mortality rates of both groups were similar: 3 (15.7%) for the treatment group and 6 (46%) for controls. The remission rates for the treatment and control groups were 7 of 19 (36.8%) and 0 of 13 (0%), respectively, and the difference was statistically significant (P = .036). The mean survival period of the treatment group was significantly longer than that of the control group (P = .01). In conclusion, this combination treatment protocol resulted in higher remission rates and longer survival periods when compared with controls, as well as a remission rate that was better than the spontaneous remission rate of 5%. For this reason, and as well as because interferon- therapy has an easier route of application and a higher family compliance, we have considered this an alternative protocol for patients with subacute sclerosing panencephalitis. (J Child Neurol 2003; 18:104—108).

Journal of Child Neurology, Vol. 18, No. 2, 104-108 (2003)
DOI: 10.1177/08830738030180020701


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. Anlar Preliminary Results for Treatments in Subacute Sclerosing Panencephalitis Have Problems? J Child Neurol, June 1, 2004; 19(6): 463 - 463. [PDF]

				O. F. Aydin, N. Senbil, and Y. K. Y. Gurer Response to Dr Anlar J Child Neurol, June 1, 2004; 19(6): 463 - 464. [PDF]

				G. G. Gascon Randomized Treatment Study of Inosiplex Versus Combined Inosiplex and Intraventricular Interferon-{alpha} in Subacute Sclerosing Panencephalitis (SSPE): International Multicenter Study J Child Neurol, December 1, 2003; 18(12): 819 - 827. [Abstract] [PDF]